These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 263185)

  • 21. [Results of determination of plasma methoxydopa in parkinsonian patients with or without dyskinesia induced by L-Dopa].
    Perret J; Feuerstein C; Pellat J; Serre F; Gavend M; Tanche M
    Rev Neurol (Paris); 1977 Nov; 133(11):627-36. PubMed ID: 601391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Reports on mental disorders in Parkinson disease in relation to treatment with L-dopa].
    Agostino R; Fabri S
    Riv Neurobiol; 1983; 29(4):577-84. PubMed ID: 6678478
    [No Abstract]   [Full Text] [Related]  

  • 23. Enteric-coated L-dopa (prodopa). A new approach to L-dopa therapy in Parkinson's disease.
    Gilligan B; Hancock R
    Med J Aust; 1975 Nov; 2(22):824-6. PubMed ID: 1207582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Use of dihydroergotamine in the prevention and treatment of orthostatic hypotension syndromes in patients with parkinsonism treated with L-dopa].
    Jubert Gruart J; Balcells Riba M
    Arch Neurobiol (Madr); 1974; 37(4):401-12. PubMed ID: 4433212
    [No Abstract]   [Full Text] [Related]  

  • 25. [Motor fluctuations in Parkinson disease: risk factors].
    Grandas F; Luquin MR; Rodríguez M; Vaamonde J; Lera G; Obeso JA
    Neurologia; 1992 May; 7(5):89-93. PubMed ID: 1389297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Dyskinesias induced by L-DOPA in Parkinson patients].
    García de Yébenes J; Muradas V; Bazán E; Reiriz J; Mena MA
    Arch Neurobiol (Madr); 1985; 48(4):197-209. PubMed ID: 4074075
    [No Abstract]   [Full Text] [Related]  

  • 27. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to L-dopa and evolution of motor fluctuations in the early phase of treatment of Parkinson's disease.
    Shif M; Kempster PA
    Clin Exp Neurol; 1994; 31():38-42. PubMed ID: 7586663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Long-term syndrome in the treatment of parkinsonism with L-dopa and decarboxylase an inhibitor].
    Chouza C; Romero S; Gomensoro JB
    Neurol Neurocir Psiquiatr; 1976; 17(4):255-68. PubMed ID: 828242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Therapeutic experiences with a slow-release preparation of L-dopa (Madopar "HBS") in patients with advanced Parkinson disease].
    Poewe W; Kleedorfer B; Gerstenbrand F
    Nervenarzt; 1989 May; 60(5):294-8. PubMed ID: 2739822
    [No Abstract]   [Full Text] [Related]  

  • 31. [Long-term problems of levodopa therapy in Parkinson disease].
    Albani C; Asper R; Baumgartner G
    Schweiz Med Wochenschr; 1987 Mar; 117(10):347-53. PubMed ID: 3105050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parkinson's disease: progression and mortality in the L-DOPA era.
    Di Rocco A; Molinari SP; Kollmeier B; Yahr MD
    Adv Neurol; 1996; 69():3-11. PubMed ID: 8615142
    [No Abstract]   [Full Text] [Related]  

  • 33. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Computerised brain electrical activity findings of parkinson patients suffering from hyperkinetic side effects (hypersensitive dopamine syndrome) and a review of possible sources.
    Fünfgeld EW
    J Neural Transm Suppl; 1995; 46():351-65. PubMed ID: 8821071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Abnormal movements of patients with Parkinsonism treated with L-dopa and anomalies of dopamine metabolism].
    Lhermitte F; Rosa A; Comoy E
    Rev Neurol (Paris); 1977 Jan; 133(1):3-11. PubMed ID: 847319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
    Greene P; Cote L; Fahn S
    Adv Neurol; 1993; 60():703-6. PubMed ID: 8420214
    [No Abstract]   [Full Text] [Related]  

  • 37. Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease.
    Brusa L; Petta F; Pisani A; Moschella V; Iani C; Stanzione P; Miano R; Finazzi-Agrò E
    Neurology; 2007 May; 68(18):1455-9. PubMed ID: 17470746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
    Mazzella L; Yahr MD; Marinelli L; Huang N; Moshier E; Di Rocco A
    Parkinsonism Relat Disord; 2005 May; 11(3):151-5. PubMed ID: 15823479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Long-term l-DOPA therapy for parkinsonism and its pathochemical aspect].
    Petelin LS; Vartanian KZ; Romenskaia LKh
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1977; 77(12):1810-3. PubMed ID: 602554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [5 years of experience in the treatment of parkinsonism with L-dopa and its combination with Ro4-4602].
    Romero S; Chouza C; Gomensoro JB
    Neurol Neurocir Psiquiatr; 1976; 17(4):239-54. PubMed ID: 1018727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.